Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCITRIOL vs NALBUPHINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcitriol, the active form of vitamin D, binds to vitamin D receptors (VDR) in target tissues, modulating gene transcription. It increases intestinal calcium and phosphate absorption, enhances renal tubular reabsorption of calcium, and promotes bone mineralization by stimulating osteoblast activity.
Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.
Management of hypocalcemia in patients undergoing chronic renal dialysis,Secondary hyperparathyroidism in patients with chronic kidney disease not yet on dialysis,Hypoparathyroidism (post-surgical, idiopathic, or pseudohypoparathyroidism),Off-label: Vitamin D-dependent rickets type I and II, osteoporosis (as an adjunct)
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
0.25-0.5 mcg orally once daily, may increase by 0.25 mcg/day at 4-8 week intervals; maximum 2 mcg/day.
10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.
5–8 hours (terminal) in normal renal function; prolonged up to 18–24 hours in chronic kidney disease (CKD) due to reduced clearance.
Terminal elimination half-life is approximately 5 hours (range 3-6 hours) in adults; prolonged in hepatic impairment.
Primarily metabolized in the kidney and intestine via 24-hydroxylase (CYP24A1) to inactive metabolites (e.g., calcitroic acid). No major hepatic cytochrome P450 involvement.
Hepatic via glucuronidation; primarily metabolized by UGT2B7; minor CYP450 involvement.
Renal (fecal after biliary excretion of metabolites): ~10% unchanged in urine; ~70% as metabolites in feces via bile.
Primarily hepatic metabolism (CYP3A4 and glucuronidation); <5% excreted unchanged in urine; ~70% excreted as metabolites in urine, ~30% in feces.
~99% bound to vitamin D-binding protein (DBP) and albumin.
Approximately 50% bound to plasma proteins, primarily albumin.
0.5–1.0 L/kg (indicates extensive tissue distribution, primarily to kidney, intestine, bone).
Approximately 2.6 L/kg (range 1.6-3.8 L/kg); indicates extensive tissue distribution.
Oral: ~70% (rapidly absorbed from small intestine). Intravenous: 100%.
Intramuscular and subcutaneous: approximately 80%; oral: low (extensive first-pass metabolism, <20% oral bioavailability).
GFR 15-59 m L/min: initial dose 0.25 mcg orally once daily; GFR <15 m L/min: avoid use or use with caution, dose adjustment not established.
Cr Cl 30-50 m L/min: administer 75% of normal dose; Cr Cl 10-29 m L/min: administer 50% of normal dose; Cr Cl <10 m L/min: avoid use or use with extreme caution.
No specific guidelines for Child-Pugh; use with caution in severe hepatic impairment as calcitriol metabolism may be altered.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50% or avoid.
Neonates and children: initial 0.25 mcg orally once daily; may increase by 0.25 mcg at 2-4 week intervals as needed; maximum 2 mcg/day.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Start at low end of dosing range (0.25 mcg once daily) due to possible decreased renal function; monitor serum calcium and phosphorus closely.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
None officially designated by FDA. However, excessive administration may lead to hypercalcemia, hypercalciuria, and hyperphosphatemia, with risk of soft tissue calcification and renal toxicity.
Risk of respiratory depression, abuse, misuse, and addiction; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Hypercalcemia risk: avoid excessive dosing; monitor serum calcium, phosphate, and alkaline phosphatase regularly,Hypercalciuria: may cause nephrolithiasis; maintain adequate hydration,Digitalis toxicity: hypercalcemia increases risk; monitor cardiac status,Adynamic bone disease: excessive suppression of PTH in dialysis patients may lead to low bone turnover,Aluminum intoxication: concurrent use of aluminum-containing phosphate binders may increase toxicity
Respiratory depression; abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; severe hypotension; head injury and increased intracranial pressure; severe hepatic or renal impairment.
Hypercalcemia or evidence of vitamin D toxicity,Hypersensitivity to calcitriol or any component of the formulation,Hyperphosphatemia (unless adequately managed)
Hypersensitivity to nalbuphine or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; suspected or known gastrointestinal obstruction; use of MAOIs within 14 days.
High dietary calcium intake may increase risk of hypercalcemia; advise consistent calcium intake per healthcare provider. No specific restrictions with other foods.
No specific food interactions. Avoid grapefruit juice as it may theoretically increase nalbuphine levels (CYP3A4 substrate, though major metabolism via glucuronidation). Maintain adequate hydration to prevent constipation.
Calcitriol is the active form of vitamin D. At therapeutic doses, no increased risk of major malformations has been consistently demonstrated. However, excessive doses (hypercalcemia) during pregnancy can lead to fetal hypercalcemia, aortic stenosis, retinopathy, and intellectual disability. First trimester: No clear teratogenicity at normal doses. Second and third trimesters: Maternal hypercalcemia from overdosage may cause fetal hypercalcemia and adverse effects. Avoid doses causing maternal serum calcium >11 mg/d L.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if potential benefit justifies risk. In first trimester, avoid unless necessary. Second and third trimesters: risk of neonatal respiratory depression, withdrawal if chronic use. Near term: may prolong labor and cause neonatal respiratory depression.
Calcitriol is present in breast milk in low concentrations. The M/P ratio is approximately 0.3–0.4. At maternal therapeutic doses, risk to the infant is minimal. Monitor infant serum calcium if maternal high doses are used.
Excreted in breast milk in small amounts; M/P ratio approximately 0.47-1.5. Limited data; caution recommended. Monitor infant for sedation and respiratory depression. Benefits of breastfeeding should outweigh risks.
Pregnancy may increase vitamin D metabolism; however, calcitriol dose adjustments are generally not required for normal pregnancies. In cases of maternal hypoparathyroidism or renal disease, dosing may need adjustment based on serum calcium levels, as increased maternal blood volume and renal clearance may decrease calcitriol levels. Titrate to maintain normocalcemia.
No specific dose adjustment recommended for pregnancy, but pharmacokinetics may be altered due to increased volume of distribution and clearance. Dosing should be on an individual basis, titrated to effect. Use lowest effective dose and shortest duration. During labor, doses should be reduced due to potential for respiratory depression in neonate.
Monitor serum calcium and phosphate levels regularly; hypercalcemia risk especially with thiazide diuretics or high calcium intake. Calcitriol has a rapid onset (hours) and short half-life, making it ideal for acute management of hypocalcemia. Avoid concurrent use of magnesium-containing antacids due to risk of hypermagnesemia.
Nalbuphine is a mixed agonist-antagonist opioid with ceiling effect on respiratory depression; less abuse liability than morphine. Useful for opioid-induced pruritus (e.g., with morphine) at low doses (0.1 mg/kg IV). May precipitate withdrawal in opioid-dependent patients. Avoid in opioid-tolerant patients on full agonists. Metabolized by liver; adjust dose in hepatic impairment. Not a controlled substance (US), but report to regulatory authorities as required.
Take exactly as prescribed, usually once daily with or without food.,Do not take additional calcium or vitamin D supplements without consulting your doctor.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, muscle weakness, confusion, or irregular heartbeat.,Avoid excessive intake of calcium-rich foods (e.g., dairy products) unless advised.,Store at room temperature away from light and moisture.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how nalbuphine affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, or death.,Do not stop suddenly after prolonged use; withdrawal symptoms may occur but are generally milder than with full agonists.,Report any signs of allergic reaction (rash, hives, swelling) or difficulty breathing immediately.,If you have been taking other opioids, inform your doctor to avoid withdrawal symptoms.,Store at room temperature away from heat, light, and moisture; keep out of reach of children.
"Dexamethasone, a potent glucocorticoid, induces the expression of the enzyme 24-hydroxylase (CYP24A1), which accelerates the catabolism of calcitriol (1,25-dihydroxyvitamin D3) into inactive metabolites. This reduces the bioavailability and therapeutic efficacy of calcitriol, potentially leading to inadequate control of hypocalcemia in patients with chronic kidney disease or hypoparathyroidism. Clinically, this interaction may manifest as declining serum calcium levels or worsening bone mineral density despite calcitriol therapy."
"Calcitriol, the active form of vitamin D, may reduce the serum concentration of aripiprazole through a proposed mechanism involving induction of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) efflux transporter. This interaction could lead to decreased systemic exposure of aripiprazole, potentially compromising its antipsychotic efficacy. Clinically, patients may experience worsening of psychotic symptoms or require dose adjustments of aripiprazole when coadministered with calcitriol."
"Calcitriol, the active form of vitamin D, may inhibit the metabolism of delavirdine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), by competing for or downregulating cytochrome P450 (CYP) enzymes, particularly CYP3A4. This can lead to elevated delavirdine plasma concentrations, increasing the risk of dose-related adverse effects such as hepatotoxicity, rash, and central nervous system toxicity. Clinically, patients may experience enhanced delavirdine toxicity without a corresponding increase in antiretroviral efficacy."
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCITRIOL vs NALBUPHINE HYDROCHLORIDE, answered by our medical review team.
CALCITRIOL is a Vitamin D Analog that works by Calcitriol, the active form of vitamin D, binds to vitamin D receptors (VDR) in target tissues, modulating gene transcription. It increases intestinal calcium and phosphate absorption, enhances renal tubular reabsorption of calcium, and promotes bone mineralization by stimulating osteoblast activity.. NALBUPHINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCITRIOL and NALBUPHINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCITRIOL is: 0.25-0.5 mcg orally once daily, may increase by 0.25 mcg/day at 4-8 week intervals; maximum 2 mcg/day.. The standard adult dose of NALBUPHINE HYDROCHLORIDE is: 10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCITRIOL and NALBUPHINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCITRIOL is classified as Category A/B. Calcitriol is the active form of vitamin D. At therapeutic doses, no increased risk of major malformations has been consistently demonstrated. However, excessive doses (hypercalcem. NALBUPHINE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if pot. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.